IFNG and neoplasm: The drug 747 is considered a selective CCR2 antagonist and has been shown to inhibit TAM recruitment and increase density of CD8+ tumor infiltrating lymphocytes as well as increase inflammatory cytokines such as IFN-γ in rodent mode.